primary endpoint

Type: Keyphrase
Name: primary endpoint
First reported 3 hours ago - Updated 3 hours ago - 1 reports

The SYMPLICITY HTN-3 Co-PI Gives His 2 Cents

I'm Dr. George Bakris, Professor of Medicine and Director of the American Society of Hypertension (ASH) Comprehensive Hypertension Center at the University of Chicago Department of Medicine, and the senior author and co-principal investigator on the SYMPLICITY ... [Published General Medicine eJournal - 3 hours ago]
First reported Apr 17 2014 - Updated 22 hours ago - 12 reports

Psoriasis Drug Meets Primary Endpoint in Phase II Study

GSK2586184 improves Psoriasis Area Severity IndexStudy JAK116679 was a phase IIa, randomized, double-blind, placebo-controlled, dose-ranging trial that evaluated the safety and efficacy of GSK2586184 (formerly GLPG0778, GlaxoSmithKline/Galapagos NV) at ... [Published P&T Community - 22 hours ago]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

VentiRx Completes Enrollment in Study of Orphan Cancer Drug

VentiRx Pharmaceuticals Inc. announced that enrollment has been completed in GOG-3003, a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ... [Published Drug Discovery and Development - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Baxter's BAX 111 treats 100% of bleeding episodes in small Phase III

Baxter International's ( BAX ) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder. BAX 111 successfully treated 22 patients who experienced bleeding ... [Published Seeking Alpha - Apr 16 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Novel therapy effective for plaque psoriasis

Share this article:Guselkumab is an investigational human monoclonal antibody directed specifically against IL-23. Patients with moderate-to-severe plaque psoriasis who received treatment with guselkumab (Janssen), an investigational human monoclonal ... [Published The Clinical Advisor - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 2 reports

SANTEN PHARMACEUTICAL : Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis NI-PSU

By a News Reporter-Staff News Editor at Pharma Business Week -- Santen Inc. , the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. ( Osaka, Japan ), announced that SAKURA (Study Assessing double-masKed Uveitis ... [Published 4 Traders - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

CANCER TREATMENT : New Findings Reported from Memorial Sloan-Kettering Cancer Center Describe Advances in Clinical Trials and Studies

By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Clinical Research have been published. According to news originating from New York City , New York , by NewsRx correspondents, research stated, "Many cancer patients ... [Published 4 Traders - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

BAXTER : Blood Disease Treatment Meets Primary Endpoint

By Michael CaliaBaxter International Inc. (BAX) on Wednesday said its treatment for a blood disorder has met the primary efficacy endpoint in a Phase three study.The company said it intends to file for U.S. Food and Drug Administration approval for the ... [Published 4 Traders - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Prana Biotechnology Is Still A Short After Recent Alzheimer's Failure

By Long Term Bio :Recently Prana Biotechnology ( PRAN ) had announced that its phase 2 trial testing patients with Alzheimer 's disease had failed. Prana fell as much as 76% to a low of $2.51 per share in one day on the published Alzheimer's disease results, ... [Published BioPortfolio - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 3 reports

Lexicon Pharma's Diabetes Drug LX4211 Hits Primary Endpoint In Trial

By Estel Grace MasangkayLexicon Pharmaceuticals announced positive, top-line results from the Phase II clinical trial of its investigational drug LX4211 in Type 1 diabetes. The trial achieved the primary endpoint of reducing mealtime insulin in patie ... [Published Pharmaceutical Online - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Diabetes Drug LX4211 Achieves Primary Endpoint in Phase II Trial

Need for mealtime insulin reducedPositive results have been reported from a phase II clinical trial of LX4211 (Lexicon Pharmaceuticals) in patients with type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several ... [Published P&T Community - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Late-Stage Trial Supports Efficacy of Obeticholic Acid in Patients With Biliary Cirrhosis

Data expected to be submitted to FDA at end of 2014Positive efficacy and safety results from the phase III POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) were presented April 12 at the International Liver Congress ... [Published P&T Community - Apr 14 2014]
Entities: Acid, biliary, Cirrhosis

Quotes

...Torsello said. "The long-term data reinforce the clinical leadership of the Endurant stent graft in an all-comer patient population." ENGAGEThe ENdurant Stent Graft NAtural Selection Global Postmarket REgistry (ENGAGE) demonstrates Medtronic's unmatched commitment to clinical research...
...Verhagen said. "The data also show that the Endurant stent graft successfully broadens patient eligibility for standard EVAR."
At the time of the financing Cytos was running out of options, though. Talking to shareholders in 2012, Cytos CFO Harry Welten said: "What is the alternative to financing this? Why do you think we laid off 72 out of 82 people last August?" Without a big licensing deal to fund development, the debt package was the only way for Cytos to see if its allergy drug could succeed...
"We at Galapagos are pleased to hear that GSK2586184 met the primary endpoint in GSK's psoriasis study.  This is the second selective JAK1 inhibitor and candidate drug based on Galapagos' novel target approach to show efficacy in patients.  The next patient readout from our pipeline is expected in June 2014: our Phase 2 Proof of Concept study with GLPG0974, a fully proprietary and novel mode of action in ulcerative colitis" said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos

More Content

All (1309) | News (1201) | Reports (0) | Blogs (86) | Audio/Video (0) | Fact Sheets (1) | Press Releases (16)
sort by: Date | Relevance
Durable T-VEC Responses Fail to Prolong Surviva... [Published OncLive - 1 hour ago]
The SYMPLICITY HTN-3 Co-PI Gives His 2 Cents [Published General Medicine eJournal - 3 hours ago]
Endurant AAA Stent Graft from Medtronic Continu... [Published Investor's Business Daily - 5 hours ago]
Endurant AAA Stent Graft from Medtronic Continu... [Published Nasdaq - 6 hours ago]
US FDA approves ofatumumab [Published Express Pharma - 7 hours ago]
Nasdaq volatility delays IPO, Almirall pulls dr... [Published FierceBiotech - 12 hours ago]
Renal denervation: latest trial shows technique... [Published Irish Medical Times - 12 hours ago]
NEWS FROM THE AAN SECTIONS: Women's Issues in N... [Published Neurology Today - 16 hours ago]
Two Enterovirus 71 Vaccines Perform Well in Pha... [Published Neurology Today - 16 hours ago]
FDA Grants Full Approval to Ofatumumab (Arzerra... [Published General Medicine eJournal - 18 hours ago]
Psoriasis Drug Meets Primary Endpoint in Phase ... [Published P&T Community - 22 hours ago]
Promising Results Reported for Remogliflozin Et... [Published P&T Community - 22 hours ago]
Cohen’s Point72 Asset Management buys a stake i... [Published Yahoo! Finance - 22 hours ago]
Good News for Cleveland BioLabs [Published Yahoo! Finance - 22 hours ago]
GSK2586184 met primary endpoint in Phase 2a pso... [Published moneyextra - 22 hours ago]
Arzerra Plus Chlorambucil Gets FDA Nod [Published Chemotherapy Advisor - 23 hours ago]
VentiRx Completes Enrollment in Study of Orphan... [Published Drug Discovery and Development - Apr 17 2014]
Galapagos NV Release: GSK2586184 Met Primary En... [Published BioSpace - Apr 17 2014]
Abbott Tests Bioresorbable Scaffold in Hope of ... [Published QMED - Apr 17 2014]
Per Lesion Ultrasound in Prostate Cancer Active... [Published American Journal of Public Health - Apr 17 2014]
GlaxoSmithKline and Galapagos succeed in psoria... [Published FierceBiotech - Apr 17 2014]
Actelion Beats on Q1 Earnings and Sales [Published Yahoo! Finance - Apr 17 2014]
Baxter’s BAX 111 meets Ph III primary efficacy ... [Published Pharma Letter - Apr 17 2014]
Lialda to save Shire's Q1 results [Published Invezz - Apr 17 2014]
GSK2586184 meets primary endpoint in Phase 2a p... [Published Noodls - Apr 17 2014]
Palliative RT Research in Prostate Cancer: Unde... [Published Cancernetwork.com - Apr 17 2014]
Galapagos: GSK2586184 Meets Primary Endpoint In... [Published RTTNews.com - Apr 17 2014]
Novel therapy effective for plaque psoriasis [Published The Clinical Advisor - Apr 17 2014]
GSK2586184 met primary endpoint in Phase 2a pso... [Published Virtual Strategy Magazine - Apr 17 2014]
BRIEF-Galapagos says GSK2586184 met primary end... [Published Reuters UK - Apr 17 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Baxter Meets Primary Efficacy Endpoint in Phase... [Published Business Wire Health News - Apr 16 2014]
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter's Phase 3 study of its investigational recombinant treatment BAX 111, met its primary endpoint of success in treating bleeding events for patients with hereditary von Willebrand disease. ...
LX4211 Achieves Positive Results In Type 1 Diab... [Published PR Newswire: Health - Apr 14 2014]
THE WOODLANDS, Texas, April 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime ...
Alkermes' Phase III trial of schizophrenia drug... [Published PBR - News - Apr 10 2014]
Irish based biopharmaceutical company Alkermes has reported positive topline results from a randomized, double-blind, placebo-controlled Phase III clinical trial of its new, long-acting injectable antipsychotic agent aripiprazole lauroxil for the treatment ...
Spironolactone May Benefit Some HF Patients (CM... [Published MedPageToday.com - medical news plus CME for ph ... - Apr 09 2014]
(MedPage Today) -- The TOPCAT trial of spironolactone for patients with heart failure and a preserved ejection fraction failed to meet its primary endpoint, but showed a modest reduction in heart failure hospitalizations with the drug, final results ...
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib pl... [Published EON Consumer - Apr 06 2014]
NEW YORK--(EON: Enhanced Online News)--Pfizer Inc. today announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib (PD-0332991) in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
GSK2586184 met primary endpoint in Phase 2a pso... [Published GlobeNewswire: Acquisitions News - Apr 17 2014]
Sobi: Kiobrina pivotal phase 3 study did not me... [Published GlobeNewswire: Biotechnology News - Mar 26 2014]
Sobi: Kiobrina pivotal phase 3 study did not me... [Published GlobeNewswire: Biotechnology News - Mar 26 2014]
Endocyte Announces Phase 2b TARGET Trial Result... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Onconova Announces Results From Phase 3 ONTIME ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.